Arecor will apply its biologics stabilisation capabilities to create improved formulations of therapeutic proteins in Lilly’s pipeline.
“The next generation of protein and peptide therapeutics present significant formulation challenges. Arecor's stabilisation tools may enable new products and presentations…without additional processing or changes to standard manufacturing practices”, Tom Saylor, CEO of Arecor, said.